- Bundibugyo Ebola outbreak in DRC and Uganda – where are the vaccines?
- Zimbabwe Dismantles 31 Drug Bases as Nearly 3 000 Suspects Are Taken to Court
- Africa Pushes Back Against US Travel Ban Linked to Ebola, Calls for Science-Driven Global Response
- In Zimbabwe, Relatives Could Now Be Called to Donate Blood for Patients
- US Suspends Entry of Travelers From Uganda, DRC Over Ebola Outbreak Fears
South Africa Launches Bid to Produce Lenacapavir as Region Seeks HIV Prevention Breakthrough
Michael Gwarisa South Africa has taken a significant step toward expanding access to next-generation HIV prevention by launching a process aimed at manufacturing lenacapavir, a long-acting injectable drug widely seen as a potential game-changer in the fight against HIV. The initiative forms part of a broader strategy by the government to strengthen regional pharmaceutical
Read More
Denmark Eliminates Mother-to-Child Transmission of HIV and Syphilis
Michael Gwarisa World Health Organization has certified Denmark as having eliminated mother-to-child transmission of both HIV and syphilis, marking a major public health milestone and making the country the first in the European Union to reach this goal. The certification follows a rigorous assessment process conducted by WHO’s Regional Validation Committee in June 2025 and
Read More
HIV Response Faces Uncertainty as Zimbabwe Halts US Health Negotiations, Experts Warn
Michael Gwarisa Zimbabwe’s HIV response could face serious disruption following the Government’s decision to halt negotiations on a proposed US$350 million health funding agreement with the United States, public health experts have warned. The proposed agreement was being negotiated between the Government of Zimbabwe and the US Embassy in Harare, acting on behalf of Washington
Read More
Zimbabwe Launches Revolutionary HIV Prevention Program with Lenacapavir
Watch: Zimbabwe Launches Lenacapavir: New HIV Prevention Injection With 99.9% Protection Michael Gwarisa In a major step forward for HIV prevention, Zimbabwe has officially launched the rollout of Lenacapavir, a long-acting injectable drug that provides new protection options for communities at high risk of HIV infection. Zimbabwe joins South Africa, Kenya, Zambia, and Eswatini among
Read More
What the Science Says About Lenacapavir, Its Effectiveness, Side Effects and Zimbabwe’s HIV Prevention Push
Michael Gwarisa Zimbabwe has set the stage for the rollout of Lenacapavir, a long acting injectable HIV prevention medicine that is expected to significantly strengthen the country’s HIV response. The injectable drug, which is administered only twice a year, is being introduced as part of Zimbabwe’s expanded HIV prevention strategy targeting people at high risk
Read More
Despite January Target, Zimbabwe Yet to Launch Lenacapavir PrEP Programme Rollout
Michael Gwarisa Zimbabwe has delayed the rollout of Lenacapavir, a long-acting injectable PrEP drug for HIV prevention, as the Ministry of Health awaits ministerial approval to announce official launch dates. The delay has sparked questions from communities and advocates eager to access the new HIV prevention option. Speaking to HealthTimes, Dr Owen Mugurungi confirmed that
Read More
South Africa Joins Zimbabwe in Testing Locally Developed HIV Vaccine
Michael Gwarisa In a move expected to reshape the regional HIV response, South Africa has become the second country in sub-Saharan Africa after Zimbabwe to launch trials of a locally developed HIV vaccine. The vaccine trials, which were first launched in Zimbabwe in August 2025, will be conducted at three sites: the Mutala Trust Clinical
Read More
ZNASP IV Review Shows HIV Gains Amid Lingering Inequalities
Kuda Pembere Zimbabwe made significant gains in its HIV response under the National HIV and AIDS Strategic Plan IV (ZNASP IV 2021–2025), including achieving the 95-95-95 targets for adults and reducing new infections and AIDS-related deaths, but persistent inequalities across age, sex, geography and population groups continue to undermine progress. This emerged during the ZNASP
Read More
AIDS Levy Raises US$60m in 2025 but Leaves US$140m HIV Funding Gap
Kuda Pembere Amid reduced donor funding and increased calls for domestic resource mobilisation, Zimbabwe’s AIDS levy generated about US$60 million in 2025. Speaking to HealthTimes, National AIDS Council chief executive officer Dr Bernard Madzima said the amount was far below the estimated annual requirement of US$200 million. The Zimbabwe National AIDS Levy is a statutory
Read More
No Weight Gain Worries for Zimbabwean Kids on Dolutegravir, Lancet Study Reports
Kuda Pembere Children and adolescents living with HIV in Zimbabwe who are being treated with dolutegravir are unlikely to experience excessive weight gain or unhealthy fat build-up, a major international study published in The Lancet Child & Adolescent Health. The findings come from the ODYSSEY trial, a large, long-term randomised study carried out in eight
Read More